case_images: PMC6348774_01
case_images: Prepazopanib magnetic resonance imaging suggestive of bulky disease
case_images: SAJC-8-51-g001.jpg
case_images: PMC6348774_01_SAJC-8-51-g001.jpg
case_images: F1
case_images: Response assessment MRI [Figure 1] at the end of 3 months of therapy showed significant interval increase in the size and extent of the endoluminal component, while the exoluminal nodular component shows a mild increase in size.
case_images: Postpazopanib magnetic resonance imaging suggestive of significant response
case_images: SAJC-8-51-g002.jpg
case_images: PMC6348774_01_SAJC-8-51-g002.jpg
case_images: F2
case_images: Post 3 months of pazopanib treatment, MRI [Figure 2] suggested lobulated mass, 3.0 cm away from the anal verge, and as compared to the previous scan, there was a significant decrease in the size of the mass.